摘要
目的探讨枯草杆菌二联活菌肠溶胶囊、双歧杆菌乳杆菌三联活菌片联合美沙拉嗪治疗溃疡性结肠炎的疗效。方法将100例溃疡性结肠炎患者随机分为治疗组和对照组,各50例。治疗组给予枯草杆菌二联活菌肠溶胶囊、双歧杆菌乳杆菌三联活菌片联合美沙拉嗪进行治疗,对照组给予柳氮磺胺吡啶进行治疗。比较两组的疗效和不良反应发生率。结果两组疗效比较,治疗组总有效率(90.0%)高于对照组(68.0%),两组差异有显著性(χ2=7.29,P<0.05)。治疗组不良反应发生率(8.0%)低于对照组(24.0%),两组比较差异有统计学意义(χ2=4.76,P<0.05)。结论枯草杆菌二联活菌肠溶胶囊、双歧杆菌乳杆菌三联活菌片联合美沙拉嗪治疗溃疡性结肠炎疗效确切,不良反应发生率低。
Objective To evaluate the effect of Medilac - S （ live combined Bacillus subtilis and Enterococcus faecium enteric - coated capsules） and golden bifid combined with mesalazine for ulcerative colitis patients. Methods One hundred patients with ulcerative colitis were randomly divided into treatment group （ n = 50 ） and control group （ n = 50）. The treatment group received Medilac - S and golden bifid combined with mesalazine for treatment,control group received sulfasalazine for treatment. The efficacy and adverse events of the two groups were observed. Results The total effective rate of treatment group（ 90% ） was significantly higher than control group （68%） （ P 〈 0.05 ）. Adverse reaction rate of the treatment group （8%） was significantly lower than control group （ 24% ） （ P 〈 0.05 ）. Conclusion Medilae - S and golden bifid combined with mesalazine are effective for ulcerative colitis,and the incidence of adverse reactions is low for the treatment.
出处
《临床和实验医学杂志》
2012年第21期1697-1698,共2页
Journal of Clinical and Experimental Medicine
